-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $110

Benzinga·12/09/2025 19:51:27
語音播報
Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $80 to $110.